This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in
patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background
Therapy (defined as treatment with > 4 drugs with activity against tuberculosis to which the
patient's isolate is believed to be sensitive by history or based on drug sensitivity
testing).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
Boston University Columbia University Pfizer University of Cape Town University of KwaZulu University of Texas